Rolvedon (Eflapegrastim-Xnst) Drug Interactions: 6 Moderate
Rolvedon (Eflapegrastim-Xnst) Drug Interactions
Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Rolvedon. Always confirm against the full prescribing information.
100 interactions
Cyclophosphamide
The risk or severity of pulmonary toxicity can be increased when Eflapegrastim is combined with Cyclophosphamide.
Level 1 evidence
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Eflapegrastim.
Level 2 evidence
Aducanumab
The risk or severity of adverse effects can be increased when Aducanumab is combined with Eflapegrastim.
Level 2 evidence
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Eflapegrastim.
Level 2 evidence
Alirocumab
The risk or severity of adverse effects can be increased when Alirocumab is combined with Eflapegrastim.
Level 2 evidence
Amivantamab
The risk or severity of adverse effects can be increased when Eflapegrastim is combined with Amivantamab.
Level 2 evidence
Anifrolumab
The risk or severity of adverse effects can be increased when Anifrolumab is combined with Eflapegrastim.
Level 2 evidence
Ansuvimab
The risk or severity of adverse effects can be increased when Eflapegrastim is combined with Ansuvimab.
Level 2 evidence
Anthrax immune globulin human
The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Eflapegrastim.
Level 2 evidence
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Eflapegrastim.
Level 2 evidence
Antithymocyte immunoglobulin (rabbit)
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Eflapegrastim.
Level 2 evidence
Asfotase alfa
The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Eflapegrastim.
Rolvedon (Eflapegrastim-Xnst) has 167 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Rolvedon (Eflapegrastim-Xnst) has 0 major, 6 moderate, and 161 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Rolvedon. Always confirm against the full prescribing information.